Annual Scientific Meeting 2024

Annual Scientific Meeting

The Melanoma and Skin Cancer Trials 2024 Annual Scientific Meeting will bring together leading figures in melanoma and skin cancer clinical trials to share the latest findings and foster further innovative research.

The full-day program will feature international keynote speakers, presentations on Melanoma and Skin Cancer Trials clinical research, and consumer sessions.

The Melanoma and Skin Cancer Trials 2024 Annual Scientific Meeting will be a satellite meeting of the Australasian Melanoma Conference (AMC), held 25-26 October 2024, Hyatt Regency, Sydney.

Networking Event

Drinks and canapés will be held after the Melanoma and Skin Cancer Trials 2024 Annual Scientific Meeting to facilitate networking.  

Details

Annual Scientific Meeting: 9am – 5pm TBC
Networking Event: 5pm – 6pm TBC
Date:
Thursday, 24 October 2024
Venue: Hyatt Regency, Sydney

Registration fees
Full registration for medical practitioners: $150
Concession for non-medical practitioners: $75
Registration fees include access to the Annual Scientific Meeting and the Networking Event.

Registration
Registrations are through the Australasian Melanoma Conference registration portal. You can register for:

  • Annual Scientific Meeting only; OR
  • Annual Scientific Meeting AND the Australasian Melanoma Conference.

Seats at the Annual Scientific Meeting and Networking Event are limited to the first 180 registrations.

Who should attend?

The 2024 Melanoma and Skin Cancer Trials Annual Scientific Meeting and Networking Event are relevant to those who represent the many disciplines critical to our work including:

Oncologists
Surgeons
Radiation specialists
Nurses
Dermatologists

Allied health professionals
Health economists
Epidemiologists
Statisticians
Ophthalmologists

Research scientists
Research students
Clinical trial coordinators
Data managers
Consumers / patient advocates and their families

Speakers

The program will feature international keynote speakers and a stellar line-up of leaders in their field who will discuss the latest clinical research in melanoma and skin cancer. Updates on Melanoma and Skin Cancer Trials’ research portfolio and opportunities for new research collaborations will form part of the meeting. Consumer presentations will also provide a unique perspective on our patient engagement. Speakers will be added to this webpage as planning progresses.

Meeting Chair

Prof Mark Shackelton
Prof Shackleton is Chair of the Melanoma and Skin Cancer Trials Board of Directors. He is also Director of Oncology at Alfred Health, Co-Director of Monash Partners Comprehensive Cancer Consortium, Professor of Oncology at Monash University, Director of Cancer Trials Australia, and a Victorian Cancer Agency Clinical Research Fellow. After training in medical oncology in Melbourne, he undertook PhD studies at the Walter and Eliza Hall Institute and post-doctoral work at the University of Michigan, receiving several major prizes including the 2012 Australian Science Minister’s Prize for Life Scientist of the Year.

Speaker - Melanoma and Skin Cancer Trials operations

Gabrielle Byars
Gabrielle Byars is Chief Executive of Melanoma and Skin Cancer Trials. She brings 15 years’ of cross-industry management experience in US- and Australian-led, multi-centre clinical studies and early phase investigator-initiated research in diabetes (device) and gastroenterology (vaccine). She has a biomedical background and notable success in technical projects with a variety of university and industry stakeholders in the biotechnology and medical technology industries. 

Talk: Update on Melanoma and Skin Cancer Trials operations

International keynote speakers

TBC

Speakers - Melanoma dermatology clinical trials

TBC

Speakers - Non-melanoma skin cancer clinical trials

TBC

Speakers - Merkel cell carcinoma clinical trials

TBC

Speakers - Ocular melanoma clinical trials

TBC

Speakers - Melanoma oncology clinical trials

TBC

Speakers - Primary and supportive care

TBC

Sponsors

Platinum Sponsor

Medison is a global pharma company providing accelerated access to highly innovative therapies to patients in Australia and international markets. Medison created the first multi-regional commercialisation platform, enabling partnerships with leading biotech and pharma companies to help save and improve the lives of those suffering from the most challenging diseases. For more information about Medison Pharma, visit www.medisonpharma.com

Silver Sponsor

Sponsorship opportunities available

Melanoma and Skin Cancer Trials offers a range of benefits to sponsors of its Annual Scientific Meeting. If your company is interested in sponsoring this event, please email hello@masc.org.au for further details. 

Melanoma and Skin Cancer Trials ASM 2024 organising committee

  • Prof Mark Shackleton, Board Chair of Melanoma and Skin Cancer Trials, Director of Oncology at Alfred Health, Professor of Oncology at Monash University, and Director of Cancer Trials Australia
  • Alison Button-Sloan, Chair, Melanoma and Skin Cancer Trials Consumer Advisory Panel
  • Gabrielle Byars, CEO, Melanoma and Skin Cancer Trials
  • Merrin Morrison, Marketing and Communications Manager, Melanoma and Skin Cancer Trials
  • Madeleine Muller, Administrative Officer / Clinical Trial Assistant, Melanoma and Skin Cancer Trials

Contact

Email: hello@masc.org.au
Phone: +61 3 9903 9022